Get the Stockscreener App
0.8782
2.05%
-0.0172
After Hours:
.86
-0.0182
-2.07%
Pmv Pharmaceuticals Inc stock is traded at $0.8782, with a volume of 554.79K.
It is down -2.05% in the last 24 hours and down -11.41% over the past month.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
See More
Previous Close:
$0.8954
Open:
$0.9
24h Volume:
554.79K
Relative Volume:
3.20
Market Cap:
$44.97M
Revenue:
-
Net Income/Loss:
$-51.47M
P/E Ratio:
-0.8782
EPS:
-1
Net Cash Flow:
$-47.50M
1W Performance:
-3.20%
1M Performance:
-11.41%
6M Performance:
-45.86%
1Y Performance:
-51.01%
1-Day Range:
$0.8507
$0.9043
1-Week Range:
$0.8507
$0.93
52-Week Range:
$0.81
$1.85
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
Name
Pmv Pharmaceuticals Inc
Sector
Industry
Phone
(609) 642-6670
Address
400 ALEXANDER PARK DRIVE, PRINCETON
Compare PMVP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
0.8656 | 46.76M | 0 | -51.47M | -47.50M | -1.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Upgrade | Oppenheimer | Perform → Outperform |
| May-13-24 | Initiated | Craig Hallum | Buy |
| Apr-12-24 | Initiated | Jefferies | Buy |
| Dec-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Mar-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Sep-22-21 | Upgrade | Goldman | Neutral → Buy |
| Aug-19-21 | Initiated | Oppenheimer | Perform |
| Aug-02-21 | Initiated | Guggenheim | Buy |
| Jul-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Cowen | Outperform |
| Oct-20-20 | Initiated | Evercore ISI | Outperform |
| Oct-20-20 | Initiated | Goldman | Neutral |
View All
Pmv Pharmaceuticals Inc Stock (PMVP) Latest News
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
PMV Pharmaceuticals to Participate at Upcoming Investor Conferen - GuruFocus
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences | PMVP Stock News - GuruFocus
PMV Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences on Oncology Innovation and Healthcare Advances - Nasdaq
AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 - The Manila Times
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences - GlobeNewswire
PMV Pharma CEO Reveals Latest Oncology Innovation Strategy at Two Major Healthcare Conferences - Stock Titan
D. E. Shaw & Co. Inc. Sells 16,189 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
These 3 Dividend Stocks Yield More Than 6% and Their Payouts Look Safe - The Globe and Mail
We're Keeping An Eye On PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Rate - Yahoo Finance
Crude Prices Rise on Doubts About a US-Iran Nuclear Deal - The Globe and Mail
Is Enbridge Stock Still Worth Owning After Strong Q1 Earnings? - The Globe and Mail
PMVP Advances PYNNACLE Trial with Steady Enrollment | PMVP Stock News - GuruFocus
PMV Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights | PMVP Stock News - GuruFocus
PMV Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights - GlobeNewswire
PMVP Reports First Quarter Cash Position and Operational Spendin - GuruFocus
Randy A. Bowman Appointed Chairman of the Board at Westwood Holdings Group - The Manila Times
PMV Pharmaceuticals Reports Progress in Phase 2 PYNNACLE Trial and First Quarter 2025 Financial Results - Nasdaq
JPMorgan Chase & Co. Buys 23,559 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
In the Green: PMV Pharmaceuticals Inc (PMVP) Closes at 0.87, Up/Down -7.34 from Previous Day - DWinneX
I Update My Buy Recommendation for Reddit Stock - The Globe and Mail
PMV Pharmaceuticals Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Nutshell gains IND clearance for p53 Y220C reactivator NTS-071 - BioWorld MedTech
Geode Capital Management LLC Sells 11,052 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
JPMorgan Chase & Co. Buys 336,516 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
PMV Pharmaceuticals stock hits 52-week low at $1.32 - MSN
ConocoPhillips (NYSE:COP) Receives Average Recommendation of “Buy” from Analysts - American Banking and Market News
APA Group (OTCMKTS:APAJF) Stock Price Down 9.1% – Here’s What Happened - Defense World
XP Power (OTCMKTS:XPPLF) Trading Down 12% – Should You Sell? - Defense World
PMV Pharmaceuticals (NASDAQ:PMVP) Stock Price Down 3.7% – Should You Sell? - Defense World
Dunxin Financial (NYSEAMERICAN:DXF) Stock Price Up 5.6% – Here’s What Happened - Defense World
Molecular Partners (OTCMKTS:MLLCF) Shares Down 1.4% – Should You Sell? - Defense World
PMV Pharmaceuticals patents new TP53 stabilizers - BioWorld MedTech
Alterome Therapeutics Announces New Chief Executive Officer and Chair of the Board of Directors - Business Wire
Promising Biotech Stocks To Watch Now – April 6th - Defense World
PMVP stock touches 52-week low at $1.01 amid market challenges - Investing.com Australia
PMV Pharmaceuticals stock hits 52-week low at $1.2 amid market shifts - Investing.com
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - Defense World
HC Wainwright Reiterates “Buy” Rating for PMV Pharmaceuticals (NASDAQ:PMVP) - Defense World
Layoff Tracker: Vaxart Cuts 10% of Staff After US Government Orders Vaccine Trial Halt - BioSpace
PMVP stock touches 52-week low at $1.2 amid market challenges - Investing.com Australia
PMVP stock touches 52-week low at $1.2 amid market challenges By Investing.com - Investing.com South Africa
Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing - Nasdaq
PMV Pharmaceuticals Reports Progress in Clinical Trials - TipRanks
PMV Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PMV Pharmaceuticals stock hits 52-week low at $1.32 By Investing.com - Investing.com South Africa
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference - The Manila Times
PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights - GlobeNewswire
PMV Pharmaceuticals (PMVP) Expected to Announce Quarterly Earnings on Thursday - Defense World
Pmv Pharmaceuticals Inc Stock (PMVP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pmv Pharmaceuticals Inc Stock (PMVP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mack David Henry | President and CEO |
Jan 03 '25 |
Option Exercise |
0.53 |
17,709 |
9,386 |
551,919 |
| Jalota Deepika | Chief Development Officer |
Sep 11 '24 |
Sale |
1.50 |
7,218 |
10,853 |
118,283 |
| Carulli Michael | Chief Financial Officer |
Sep 11 '24 |
Sale |
1.50 |
2,891 |
4,347 |
88,395 |
1.89%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):